Panatus forte, pills 50mg, 10pcs

Composition

1 film-coated tablet contains:

Active ingredient:

Butamirate Citrate 50.00 mg

Excipients: lactose monohydrate, povidone K-25, hypromellose 15000 MPas, talc, magnesium stearate, colloidal silicon dioxide

Film shell: hypromellose 6 MPas, titanium dioxide (E 171), iron oxide red dye (E 172), talc, propylene

glycol Pharmacological action

antitussive agent of central action

Clinical Pharmacology

Pharmacodynamics

Butamirate, the Active ingredient of Panatus Forte, is a centrally acting antitussive agent that is neither chemically nor pharmacologically related to opium alkaloids. Suppresses cough, having a direct effect on the cough center. It has a bronchodilating effect. Helps facilitate breathing by improving spirometry (reduces airway resistance) and blood oxygenation.

Pharmacokinetics

Butamirate is rapidly and completely absorbed when taken orally.

With repeated use of butamirate, its concentration in blood plasma remains linear and no accumulation is observed.

Hydrolysis of butamirate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood. These metabolites also have antitussive activity. Butamirate and its metabolites have almost the maximum (about 95%) degree of binding to plasma proteins, which causes their long half-life (T_1/2) and long-term antitussive effect. Metabolites are mainly excreted by the kidneys, and acidic metabolites are largely associated with glucuronic acid. T_1/2 is 6 hours.

Indications

Dry cough of any etiology, including whooping cough, for cough suppression in the preoperative and postoperative period, during surgical interventions and bronchoscopy.

Use during pregnancy and lactation

There are no data on the safety of using Panatus forte during pregnancy and its passage through the placental barrier. The drug is not recommended for use in the first trimester of pregnancy. In the second and third trimesters of pregnancy, the drug can be used only after consulting a doctor. Given the lack of data on the excretion of butamirate in breast milk, the use of Panatus® forte during breastfeeding is not recommended.

Contraindications

Hypersensitivity to the components of the drug, pregnancy (I trimester), breastfeeding, children under 12 years of age, lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.

Side effects

World Health Organization (WHO)classification of the incidence of side effects:

very common ≥ 1/10

common ≥ 1/100 to < 1/10

uncommon ≥ 1/1000 to < 1/100

rare ≥ 1/10000 to < 1/1000

very rare ≥ 1/100000, including individual reports.

Central nervous system (CNS)disorders:

rarely: drowsiness, dizziness.

From the digestive system:

rare: nausea, vomiting, diarrhea.

From the side of the skin:

rare: exanthema.

Other services: allergic reactions may occur.

Interaction

No drug interactions have been described for butamirate.

Due to the fact that butamirate suppresses the cough reflex, the simultaneous use of expectorants should be avoided in order to avoid accumulation of sputum in the respiratory tract.

During the period of use of Panatus® forte, the use of ethanol, as well as drugs that depress the central nervous system (sleeping pills, neuroleptics, tranquilizers, etc. ) is not recommended.

How to take, course of use and dosage

Inside, before eating.

Children over 12 years of age: 1 tablet 1-2 times a day; adults: 1 tablet 2-3 times a day.

If the cough persists for more than 5-7 days, you should consult a doctor.

Overdose

Symptoms: drowsiness, dizziness, nausea, vomiting, abdominal pain, diarrhea, irritability, impaired coordination of movements, low blood pressure.

Treatment: wash out the stomach, prescribe activated charcoal, laxatives, and take measures to maintain the function of the cardiovascular and respiratory systems. There is no antidote. Treatment is symptomatic.

Description

Round, biconvex tablets with a chamfer, covered with a film-coated red-brown color.

View at the break: white rough mass with a red-brown film shell.

Special instructions

Pregnancy (II-III trimesters).

Contraindicated in children under 12 years of age.

It is contraindicated in patients with lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.

One film-coated tablet contains 285 mg of lactose. At each dose of the drug in accordance with the instructions for use, the patient takes up to 285 mg of lactose. Panatus forte is not used in patients with lactase deficiency, lactose intolerance, or glucose-galactose malabsorption syndrome. If after 5-7 days of using Panatus forte, the cough does not stop, you should consult a doctor.

Panatus forte can cause drowsiness, so caution should be exercised when driving vehicles and working with complex technical devices that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Film-coated tablets,50 mg.

10 tablets in a blister of PVC/Al-foil (PVC/Al-foil).

1 blister together with the instructions for use is placed in a cardboard pack.

Storage conditions

At a temperature not exceeding 25 ° C, in the original packaging.

Keep out of reach of children.

Shelf

life is 5 years.

Do not use the drug after the expiration date.

Active ingredient

Butamirate

Dosage form

Tablets

Description

Children as prescribed by a doctor, Children over 12 years of age, For adults, Pregnant Women in the second and third trimester as prescribed by a doctor

Indications

Whooping cough, Preparation for bronchoscopy, Cough, Cold